Urteste S.A. to Launch Panuri Test Clinical Study Q3 2025
Urteste S.A. has completed development of its Panuri test for pancreatic cancer and plans to begin clinical trials in...
Optima II Trial Shows Long-Term Durability of Zusduri in Bladder Cancer
A five-year long-term extension study of the Phase 2b OPTIMA II trial, published in Clinical Genitourinary Cancer, demonstrated durable...
Arrivent’s Pivotal Phase 3 Furvent Data for Firmonertinib Projected Early 2026
ArriVent BioPharma anticipates topline data from its global Phase 3 FURVENT trial in early 2026. The trial is evaluating...
nkgen’s FDA Authorization for Neurodegenerative Disease Treatment
NKGen Biotech has received FDA authorization for an Expanded Access Program (EAP) to explore the use of its cryopreserved,...
Oruka Therapeutics Gets IND Clearance for ORKA-001 Psoriasis Trial
Oruka Therapeutics received FDA clearance for its Investigational New Drug (IND) application to begin the Phase 2a clinical trial,...
HeartFlow Plaque Analysis Impacts Coronary Artery Disease Management
Heartflow, Inc. announced positive data from the DECIDE Registry, demonstrating that their AI-powered Heartflow Plaque Analysis led to treatment...
Five Abstracts on SPRINT® PNS at ASPN 2025
SPR Therapeutics presented data at the American Society of Pain & Neuroscience (ASPN) Annual Conference demonstrating the effectiveness of...
Actuate’s Ewing Sarcoma Trial Shows Promise in Pediatric Sarcomas
Actuate Therapeutics has completed Phase 1 of its elraglusib study in pediatric patients with refractory cancers, observing promising results...
Lisata and WarpNine Announce ILSTA Trial Completion & Data
Lisata Therapeutics and WARPNINE Incorporated completed patient enrollment in their Phase 1b/2a iLSTA trial in Australia. The trial evaluates...
Keros Doses First Patient in Phase 3 Trial of Elritercept
Keros Therapeutics initiated Phase 3 trials for elritercept, a treatment for transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS)....